To investigate the clinical efficacy of movable ¹²⁵I particle strip combined with percutaneous transhepatic cholangiodrainage (PTCD) in the treatment of Hilar Cholangiocarcinoma (HCCA).

Forty HCCA patients were retrospective analyzed as the research objects from Affiliated Hospital of Jiangnan University from October 2020 to October 2021, and they were divided into the study group (19 cases) and the control group (21 cases) according to the different treatment. Patients in study group were treated by movable ¹²⁵I radioactive seed implantation combined with PTCD, and the control group patients were treated by straight ¹²⁵I radioactive seed implantation combined with percutaneous biliary stenting. The improvement of liver function before and after surgery, time to drainage patency, operation time, operation cost, incidence of postoperative complications and short survival time were compared and analyzed between the two groups.

After treatment, the indexes of abnormal liver function in both groups were significantly lower than those before treatment. There was no significant difference in the remission of liver function between the two groups (P > 0.05). The drainage patency time of the study group was 167.0 d better than that of the control group (152.0 d). The incidence of biliary tract infection was 15.79% and 61.90% in the two groups, respectively, which was statistically significant.The median operation time in the study group was about 20 minutes shorter than that in the control group, and the median operation cost in the study group was about 3 000 yuan less than that in the control group,and the incidence of postoperative complications in the study group was significantly lower than that in the control group (all P < 0.05). Patients in two groups were followed up for 6 to 20 months, and the median follow-up time was 13 months. The total number of particle strip changes in the observation group was 18, and short-term survival rate was higher than that of the control group (78.95% vs 52.38%).

Movable ¹²⁵I radioactive seed strip implantation combined with PTCD is generally safe and effective in the treatment of HCCA patients, with shorter operative time, lower incidence of biliary tract infections, and higher short-term survival rates.